Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Saiman, L. Articles by Whittier, S. Search for Related Content PubMed PubMed Citation Articles by Saiman, L. Articles by Whittier, S.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, November 2001, p. 3942-3945, Vol. 39, No. 11
0095-1137/01/$04.00+0   DOI: 10.1128/JCM.39.11.3942-3945.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Identification and Antimicrobial Susceptibility of Alcaligenes xylosoxidans Isolated from Patients with Cystic Fibrosis

Lisa Saiman,^* Yunhua Chen, Setareh Tabibi, Pablo San Gabriel, Juyan Zhou, Zhenling Liu, Lena Lai, and Susan Whittier

Department of Pediatrics, Columbia University, New York, New York

Received 29 June 2001/Returned for modification 7 August 2001/Accepted 21 August 2001

	ABSTRACT

Top Abstract Introduction Materials and Methods Results Discussion References

In the past decade, potential pathogens, including Alcaligenes species, have been increasingly recovered from cystic fibrosis (CF) patients. Accurate identification of multiply antibiotic-resistant gram-negative bacilli is critical to understanding the epidemiology and clinical implications of emerging pathogens in CF. We examined the frequency of correct identification of Alcaligenes spp. by microbiology laboratories affiliated with American CF patient care centers. Selective media, an exotoxin A probe for Pseudomonas aeruginosa, and a commercial identification assay, API 20 NE, were used for identification. The activity of antimicrobial agents against these clinical isolates was determined. A total of 106 strains from 78 patients from 49 CF centers in 22 states were studied. Most (89%) were correctly identified by the referring laboratories as Alcaligenes xylosoxidans. However, 12 (11%) strains were misidentified; these were found to be P. aeruginosa (n = 10), Stenotrophomonas maltophilia (n = 1), and Burkholderia cepacia (n = 1). Minocycline, imipenem, meropenem, piperacillin, and piperacillin-tazobactam were the most active since 51, 59, 51, 50, and 55% of strains, respectively, were inhibited. High concentrations of colistin (100 and 200 µg/ml) inhibited 92% of strains. Chloramphenicol paired with minocycline and ciprofloxacin paired with either imipenem or meropenem were the most active combinations and inhibited 40 and 32%, respectively, of strains. Selective media and biochemical identification proved to be useful strategies for distinguishing A. xylosoxidans from other CF pathogens. Standards for processing CF specimens should be developed, and the optimal method for antimicrobial susceptibility testing of A. xylosoxidans should be determined.

	INTRODUCTION

Top Abstract Introduction Materials and Methods Results Discussion References

Cystic fibrosis (CF) is the most common life-shortening disease caused by a recessive autosomal gene in the Caucasian population and afflicts about 60,000 patients worldwide, approximately 30,000 of whom are cared for in the United States (21). While the genetic defect in CF is known, the relationship between abnormal CF transmembrane conductance regulator and chronic pulmonary disease is not yet fully understood (22). Chronic pulmonary disease is characterized by a vicious cycle of inflammation and infection and is the major cause of morbidity and mortality. The pathogens of CF are well characterized and include Staphylococcus aureus, nontypeable Haemophilus influenzae, Pseudomonas aeruginosa, and Burkholderia cepacia (10).

During the past decade, several additional potential pathogens have been recovered from CF patients, including nontuberculous mycobacteria (19), Stenotrophomonas maltophilia (3), and Alcaligenes species, particularly Alcaligenes xylosoxidans (29). As reported to the U.S. Cystic Fibrosis Foundation's National Patient Registry in 1996 and 1997, 1.9 and 2.7% of all CF patients harbored Alcaligenes spp. (7, 8). As determined by a research laboratory participating in a phase III trial of aerosolized tobramycin in CF patients who were 6 years of age, 8.7% of 520 patients harbored A. xylosoxidans (1). At present, it is unclear if A. xylosoxidans causes clinical disease in CF patients or merely colonizes the respiratory tract (4, 17).

However, accurate identification of multiply antibiotic-resistant gram-negative bacilli isolated from CF patients is critical to facilitate our understanding of the epidemiology of emerging pathogens. Furthermore, accurate identification has important implications for treatment and for the institution of infection control standards if patient-to-patient transmission is observed (26). We examined the frequency of misidentification of Alcaligenes spp. by clinical microbiology laboratories affiliated with CF care centers in the United States and determined the antimicrobial susceptibility of these clinical isolates using the National Committee for Clinical Laboratory Standards (NCCLS) interpretative criteria for P. aeruginosa, since breakpoints for Alcaligenes spp. have not been established.

	MATERIALS AND METHODS

Top Abstract Introduction Materials and Methods Results Discussion References

Isolates tested. Clinical isolates sent to the Cystic Fibrosis Referral Center at Columbia University (24) from 1995 to 1998 identified by the referring clinical microbiology laboratories as A. xylosoxidans, Alcaligenes spp., or Alcaligenes odorans were selected for this study. All strains were isolated from CF patients cared for at accredited care centers in the United States (6). Strains had been stored at 70°C and were grown on biplates of blood agar and MacConkey agar (REMEL, Lenexa, Kans.) to confirm purity.

Several control strains were used to confirm the identification strategies used: P. aeruginosa ATCC 27853, clinical isolates of P. aeruginosa (one mucoid and one nonmucoid), A. xylosoxidans ATCC 27061 and ATCC 35655, B. cepacia ATCC 25416, a clinical strain of B. cepacia, S. maltophilia ATCC 13637, and a clinical strain of S. maltophilia. All clinical strains were isolated from CF patients.

Identification strategy for Alcaligenes spp. Isolates were confirmed as A. xylosoxidans or Alcaligenes spp. using phenotypic and genetic characteristics to distinguish Alcaligenes spp. from B. cepacia complex, S. maltophilia, or P. aeruginosa. Isolates were plated on several agar media that included DNase, namely, oxidative-fermentative polymyxin B-bacitracin-lactose (OFPBL) and Mueller-Hinton agar (BBL, Sparks, Md.), and were probed for the exotoxin A gene of P. aeruginosa (25). Plates were incubated at 35°C for 18 to 24 h and examined for growth, pigment production consistent with that of P. aeruginosa, and DNase production consistent with that of S. maltophilia. In addition, API 20 NE was used to identify the isolates to the species level (bioMerieux, Vitek, Hazelwood, Mo.).

Antimicrobial susceptibility and synergy testing. Antimicrobial susceptibility testing was performed by microbroth dilution assay using commercially prepared microtiter plates (Microtech Medical Systems, Inc., Aurora, Colo.) containing serial twofold dilutions of antibiotics (24). This assay has been shown to be comparable to agar dilution for testing the antimicrobial susceptibility of P. aeruginosa isolates from CF patients (25). As there are not yet NCCLS interpretative criteria for susceptibility breakpoints for Alcaligenes spp., the breakpoints for P. aeruginosa were used. The antimicrobial agents tested included ticarcillin-clavulanic acid (4 to 128 µg/ml), piperacillin (4 to 128 µg/ml), piperacillin-tazobactam (piperacillin component, 4 to 128 µg/ml), ceftazidime (1 to 64 µg/ml), imipenem (0.5 to 16 µg/ml), meropenem (0.5 to 16 µg/ml), ciprofloxacin (0.25 to 8 µg/ml), tobramycin (0.5 to 256 µg/ml), trimethoprim-sulfamethoxazole (trimethoprim component, 0.5 to 16 µg/ml), chloramphenicol (1 to 64 µg/ml), and minocycline (1 to 32 µg/ml). In addition to standard concentrations of antibiotics, the activity of higher concentrations of tobramycin (MIC, 16 to 256 µg/ml) such as those which could be achieved by aerosolization (20) and high concentrations of colistin (100 and 200 µg/ml) were tested. Plates were incubated at 35°C for 18 to 24 h.

Synergy studies using checkerboard dilutions of pairs of antimicrobial agents tested at clinically achievable concentrations were performed (24). The pairs of agents selected had different mechanisms of action and had been shown to have activity against B. cepacia complex (2). Fractional inhibitory concentrations (FIC) were calculated as previously described (24). FIC of <0.5 were considered synergistic, and FIC of 0.5 to <1.0 were considered additive.

	RESULTS

Top Abstract Introduction Materials and Methods Results Discussion References

Identification of isolates. A total of 106 strains from 78 patients (one to five strains per patient) from 49 CF centers in 22 states were tested in this study. The vast majority (99 of 106; 93%) were identified as A. xylosoxidans by the referring microbiology laboratories, while six were labeled Alcaligenes spp. and one was labeled Alcaligenes odorans. Of these 106 strains, 94 (89%) did not grow on OFPBL medium, did not express DNase, did not hybridize with the exotoxin A probe, and were identified by API 20 NE as A. xylosoxidans as shown in Table 1.

View this table: [in this window] [in a new window]   TABLE 1.   Identification of 106 strains previously identified as A. xylosoxidans, Alcaligenes spp., or A. odorans from CF patients

However, 12 strains exhibited phenotypic and/or genotypic properties that were not consistent with those of Alcaligenes spp. (Table 1). One strain expressed DNase, did not hybridize with the exotoxin A probe, and was identified by API 20 NE as S. maltophilia. One strain grew on OFPBL medium, was identified as B. cepacia by API 20 NE, and was confirmed as such by the B. cepacia reference laboratory (16). Ten strains hybridized with the probe for exotoxin A, including four pigment-producing strains. API 20 NE identified 9 of these 10 strains as P. aeruginosa and 1 as a Pseudomonas sp.

Antimicrobial susceptibility and synergy testing. The 94 A. xylosoxidans strains were highly resistant to antibiotics. Minocycline, imipenem, meropenem, piperacillin, and piperacillin-tazobactam had the most activity and inhibited 51, 59, 51, 50, and 55% of strains, respectively (Table 2). However, the majority of strains were resistant to the remaining agents tested.

View this table: [in this window] [in a new window]   TABLE 2.   Activity of antimicrobial agents against Alcaligenes spp. isolated from CF patients

We also examined the activity of higher concentrations of tobramycin and colistin. The majority of strains (97%) were resistant to conventional concentrations of tobramycin (MIC, >8 µg/ml). However, 38 (41%) strains were inhibited by concentrations of tobramycin achievable by aerosolization (MIC, 16 to 256 µg/ml), while the MICs for 53 (56%) strains were >256 µg/ml. Only 8% of the A. xylosoxidans strains studied were resistant to the high concentrations of colistin tested.

Combinations of antimicrobial agents had some synergistic activity, but the FIC was <0.5 for fewer than 10% of the isolates tested (Table 3). However, additive activity was noted for some combinations, including chloramphenicol-minocycline (35%), ciprofloxacin-imipenem (27%), and ciprofloxacin-meropenem (23%).

View this table: [in this window] [in a new window]   TABLE 3.   Activity of antimicrobial agents against Alcaligenes spp. isolated from CF patients

	DISCUSSION

Top Abstract Introduction Materials and Methods Results Discussion References

Most (89%) isolates from CF patients identified as A. xylosoxidans or Alcaligenes spp. by referring clinical microbiology laboratories affiliated with U.S. CF care centers were correctly identified. However, three other gram-negative bacilli were incorrectly identified as A. xylosoxidans, as 12 (11%) strains were identified as other CF pathogens, including 10 as P. aeruginosa, 1 as S. maltophilia, and 1 as B. cepacia. Used together, selective media, biochemical identification, and molecular detection of exotoxin A proved to be useful strategies. In this study, API 20 NE consistently identified A. xylosoxidans correctly.

The CF community, the Centers for Disease Control and Prevention, and the American Society for Microbiology endorse the use of selective media for processing respiratory tract specimens from patients with CF (11, 15, 28). However, there has not been a consensus for the use of selective media other than those for B. cepacia complex, e.g., OFPBL agar or B. cepacia selective medium (13). More extensive recommendations for the use of selective media, which include mannitol salt agar, chocolate agar, sheep blood agar, and MacConkey agar, have been made by experts in CF microbiology (23). Furthermore, site visits to accredited CF care centers sponsored by the Cystic Fibrosis Foundation are made approximately every 4 years by a member of the CF center directors committee (Preston Campbell, personal communication). During these site visits, the directors of the clinical microbiology laboratories are interviewed to assess their understanding of the importance of appropriate processing of respiratory tract specimens from CF patients, including the use of selective media, and the importance of understanding newly emerging pathogens. While clinical microbiology laboratories do have their own written procedures for processing CF specimens, the American Society for Microbiology should develop and publish national standards for processing CF specimens.

The most recent NCCLS documents do not include recommendations for the optimal antimicrobial susceptibility testing method for Alcaligenes spp. nor the antimicrobial agents that should be tested. We utilized a microbroth dilution assay that we have shown to be comparable with agar dilution for testing the antimicrobial susceptibility of P. aeruginosa isolates from CF patients (25). This method, as well as the disk diffusion method, has been endorsed by the NCCLS for susceptibility testing of P. aeruginosa isolates from CF patients (18). We tested a panel of antimicrobial agents with activity against P. aeruginosa (24) and B. cepacia (2) and used susceptibility breakpoints established for P. aeruginosa. Notably, minocycline, an agent not usually included in automated commercial microbroth dilution systems, was found to be active against 51% of the isolates of A. xylosoxidans tested. The carbapenem agents and piperacillin, with or without tazobactam, were also active against these isolates of A. xylosoxidans. Earlier studies have demonstrated that imipenem, ceftazidime, -lactamase inhibitor combinations, and trimethoprim-sulfamethoxazole were most active (12, 27), although these studies did not include CF isolates.

While the clinical efficacy of synergy studies has not yet been tested, combinations of antimicrobial agents are often recommended for treatment of highly resistant pathogens such as P. aeruginosa and S. maltophilia. Thus, our findings may have implications for treatment of CF patients as well as non-CF patients with nosocomial infections caused by A. xylosoxidans (5).

There are several limitations to this study. Patients with CF frequently harbor more than one pathogen, and the referred specimens may have been mislabeled. At present, the optimal method of antimicrobial susceptibility testing for Alcaligenes spp. is unknown, and there are limited reports assessing in vivo efficacy of antibiotics in either CF or non-CF patients. The optimal methodology for susceptibility testing of colistin is under investigation (9, 14), as is the concentration deliverable by aerosolization (30).

In conclusion, further studies are needed to standardize microbiologic methodologies for identification and susceptibility testing of Alcaligenes spp. in both CF and non-CF patients. In addition, future studies should continue to address the epidemiology and the possible pathogenic role of A. xylosoxidans in CF patients. A methodology, such as API 20 NE, should be employed to verify identification of this species.

	ACKNOWLEDGMENTS

This work was supported by the U.S. Cystic Fibrosis Foundation.

We thank John J. LiPuma for confirming the identity of the Burkholderia spp. at the CF Repository for Burkholderia spp. and Anne-Sophie Morel for administrative assistance.

	FOOTNOTES

^* Corresponding author. Mailing address: Columbia University, 650 West 168th St., PH 4 West Rm. 470, New York, NY 10032. Phone: (212) 305-9446. Fax: (212) 305-9491. E-mail: LS5{at}columbia.edu.

Present address: Department of Laboratories, Meridian Health System, Neptune, N.J.

	REFERENCES

Top Abstract Introduction Materials and Methods Results Discussion References

1.	Burns, J. L., J. Emerson, J. R. Stapp, D. L. Yim, J. Krzewinski, L. Louden, B. W. Ramsey, and C. R. Clausen. 1998. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin. Infect. Dis. 27:158-163[Medline].
2.	Burns, J. L., and L. Saiman. 1999. Burkholderia cepacia infections in cystic fibrosis. Pediatr. Infect. Dis. J. 18:155-156[CrossRef][Medline].
3.	Demko, C. A., R. C. Stern, and C. F. Doershuk. 1998. Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence. Pediatr. Pulmonol. 25:304-308[CrossRef][Medline].
4.	Dunne, W. M., Jr., and S. Maisch. 1995. Epidemiological investigation of infections due to Alcaligenes species in children and patients with cystic fibrosis: use of repetitive-element-sequence polymerase chain reaction. Clin. Infect. Dis. 20:836-841[Medline].
5.	Evans, M. E., D. J. Feola, and R. P. Rapp. 1999. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann. Pharmacother. 33:960-967[Abstract].
6.	FitzSimmons, S. C. 1993. The changing epidemiology of cystic fibrosis. J. Pediatr. 122:1-9[Medline].
7.	FitzSimmons, S. C. 1997. Patient registry 1996 annual data report. Cystic Fibrosis Foundation, Bethesda, Md.
8.	FitzSimmons, S. C. 1998. Patient registry 1997 annual data report. Cystic Fibrosis Foundation, Bethesda, Md.
9.	Gales, A. C., A. O. Reis, and R. N. Jones. 2001. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J. Clin. Microbiol. 39:183-190[Abstract/Free Full Text].
10.	Gilligan, P. H. 1991. Microbiology of airway disease in patients with cystic fibrosis. Clin. Microbiol. Rev. 4:35-51[Abstract/Free Full Text].
11.	Gilligan, P. H., and S. Whittier. 1999. Burkholderia, Stenotrophomonas, Ralstonia, Brevundimonas, Comamonas, and Acidovorax, p. 526-538. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. American Society for Microbiology, Washington, D.C.
12.	Glupczynski, Y., W. Hansen, J. Freney, and E. Yourassowsky. 1988. In vitro susceptibility of Alcaligenes denitrificans subsp. xylosoxidans to 24 antimicrobial agents. Antimicrob. Agents Chemother. 32:276-278[Abstract/Free Full Text].
13.	Henry, D., M. Campbell, C. McGimpsey, A. Clarke, L. Louden, J. L. Burns, M. H. Roe, P. Vandamme, and D. Speert. 1999. Comparison of isolation media for recovery of Burkholderia cepacia complex from respiratory secretions of patients with cystic fibrosis. J. Clin. Microbiol. 37:1004-1007[Abstract/Free Full Text].
14.	Hogg, G. M., J. G. Barr, and C. H. Webb. 1998. In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii. J. Antimicrob. Chemother. 41:494-495[Free Full Text].
15.	Kiska, D. L., and P. H. Gilligan. 1999. Pseudomonas, p. 517-525. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. ASM Press, Washington, D.C.
16.	McMenamin, J. D., T. M. Zaccone, T. Coenye, P. Vandamme, and J. J. LiPuma. 2000. Misidentification of Burkholderia cepacia in US cystic fibrosis treatment centers: an analysis of 1,051 recent sputum isolates. Chest 117:1661-1665[Abstract/Free Full Text].
17.	Moissenet, D., A. Baculard, M. Valcin, V. Marchand, G. Tournier, A. Garbarg-Chenon, and H. Vu-Thien. 1997. Colonization by Alcaligenes xylosoxidans in children with cystic fibrosis: a retrospective clinical study conducted by means of molecular epidemiological investigation. Clin. Infect. Dis. 24:274-275[Medline].
18.	NCCLS. 2001. Performance standards for antimicrobial susceptibility testing, 11th informational supplement In NCCLS document M100-S11., vol. 21. NCCLS, Wayne, Pa.
19.	Olivier, K., J. R. Yankaskas, and M. R. Knowles. 1996. Nontuberculous mycobacterial pulmonary disease in cystic fibrosis. Semin. Respir. Infect. 11:272-284[Medline].
20.	Ramsey, B. W., M. S. Pepe, J. M. Quan, K. L. Otto, A. B. Montgomery, J. Williams-Warren, M. Vasiljev-K, D. Borowitz, C. M. Bowman, B. C. Marshall, S. Marshall, and A. L. Smith. 1999. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 340:23-30[Abstract/Free Full Text].
21.	Ramsey, B. W. 1996. Management of pulmonary disease in patients with cystic fibrosis. N. Engl. J. Med. 335:179-188[Free Full Text].
22.	Rosenstein, B. J., and P. L. Zeitlin. 1998. Cystic fibrosis. Lancet 351:277-282[CrossRef][Medline].
23.	Saiman, L., D. Schidlow, and A. L. Smith. 1994. Consensus statement: infection and microbiology in cystic fibrosis. Cystic Fibrosis Foundation, Bethesda, Md.
24.	Saiman, L., F. Mehar, W. W. Niu, H. C. Neu, K. J. Shaw, G. Miller, and A. Prince. 1996. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin. Infect. Dis. 23:532-537[Medline].
25.	Saiman, L., J. L. Burns, S. Whittier, J. Krzewinski, S. A. Marshall, and R. N. Jones. 1999. Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis. J. Clin. Microbiol. 37:2987-2991[Abstract/Free Full Text].
26.	Saiman, L., N. MacDonald, J. L. Burns, N. Hoiby, D. P. Speert, and D. Weber. 2000. Infection control in cystic fibrosis: practical recommendations for the hospital, clinic, and social settings. Am. J. Infect. Control 28:381-385[CrossRef][Medline].
27.	Steinberg, J. P., and C. Del Rio. 2000. Alcaligenes, p. 2465-2466. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Mandell, Douglas and Bennett's principles and practice of infectious diseases, 5th ed. Churchill Livingstone, Philadelphia, Pa.
28.	Tablan, O. C., W. J. Martone, C. F. Doershuk, R. C. Stern, M. J. Thomassen, J. D. Klinger, J. W. White, L. A. Carson, and W. R. Jarvis. 1987. Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Chest 91:527-532[Abstract/Free Full Text].
29.	Vu-Thien, H., D. Moissenet, M. Valcin, C. Dulot, G. Tournier, and A. Garbarg-Chenon. 1996. Molecular epidemiology of Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans in a cystic fibrosis center. Eur. J. Clin. Microbiol. Infect. Dis. 15:876-879[CrossRef][Medline].
30.	Weber, A., G. Morlin, M. Cohen, J. Williams-Warren, B. Ramsey, and A. Smith. 1997. Effect of nebulizer type and antibiotic concentration on device performance. Pediatr. Pulmonol. 23:249-260[CrossRef][Medline].

---

Journal of Clinical Microbiology, November 2001, p. 3942-3945, Vol. 39, No. 11
0095-1137/01/$04.00+0   DOI: 10.1128/JCM.39.11.3942-3945.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

This article has been cited by other articles:

• Kidd, T. J., Ramsay, K. A., Hu, H., Bye, P. T. P., Elkins, M. R., Grimwood, K., Harbour, C., Marks, G. B., Nissen, M. D., Robinson, P. J., Rose, B. R., Sloots, T. P., Wainwright, C. E., Bell, S. C., and the ACPinCF Investigators, (2009). Low Rates of Pseudomonas aeruginosa Misidentification in Isolates from Cystic Fibrosis Patients. J. Clin. Microbiol. 47: 1503-1509 [Abstract] [Full Text]  
• Bosch, A., Minan, A., Vescina, C., Degrossi, J., Gatti, B., Montanaro, P., Messina, M., Franco, M., Vay, C., Schmitt, J., Naumann, D., Yantorno, O. (2008). Fourier Transform Infrared Spectroscopy for Rapid Identification of Nonfermenting Gram-Negative Bacteria Isolated from Sputum Samples from Cystic Fibrosis Patients. J. Clin. Microbiol. 46: 2535-2546 [Abstract] [Full Text]  
• Kremer, T. M., Zwerdling, R. G., Michelson, P. H., O'Sullivan, B. P. (2008). Intensive Care Management of the Patient With Cystic Fibrosis. J Intensive Care Med 23: 159-177 [Abstract]  
• Goss, C. H, Burns, J. L (2007). Exacerbations in cystic fibrosis {middle dot} 1: Epidemiology and pathogenesis. Thorax 62: 360-367 [Abstract] [Full Text]  
• Zhou, J., Chen, Y., Tabibi, S., Alba, L., Garber, E., Saiman, L. (2007). Antimicrobial Susceptibility and Synergy Studies of Burkholderia cepacia Complex Isolated from Patients with Cystic Fibrosis. Antimicrob. Agents Chemother. 51: 1085-1088 [Abstract] [Full Text]  
• Van daele, S., Vaneechoutte, M., De Boeck, K., Knoop, C., Malfroot, A., Lebecque, P., Leclercq-Foucart, J., Van Schil, L., Desager, K., De Baets, F. (2006). Survey of Pseudomonas aeruginosa genotypes in colonised cystic fibrosis patients. Eur Respir J 28: 740-747 [Abstract] [Full Text]  
• Wellinghausen, N., Wirths, B., Poppert, S. (2006). Fluorescence In Situ Hybridization for Rapid Identification of Achromobacter xylosoxidans and Alcaligenes faecalis Recovered from Cystic Fibrosis Patients.. J. Clin. Microbiol. 44: 3415-3417 [Abstract] [Full Text]  
• Zhou, J., Garber, E., Desai, M., Saiman, L. (2006). Compliance of Clinical Microbiology Laboratories in the United States with Current Recommendations for Processing Respiratory Tract Specimens from Patients with Cystic Fibrosis. J. Clin. Microbiol. 44: 1547-1549 [Abstract] [Full Text]  
• Van daele, S., Verhelst, R., Claeys, G., Verschraegen, G., Franckx, H., Van Simaey, L., de Ganck, C., De Baets, F., Vaneechoutte, M. (2005). Shared Genotypes of Achromobacter xylosoxidans Strains Isolated from Patients at a Cystic Fibrosis Rehabilitation Center. J. Clin. Microbiol. 43: 2998-3002 [Abstract] [Full Text]  
• San Gabriel, P., Zhou, J., Tabibi, S., Chen, Y., Trauzzi, M., Saiman, L. (2004). Antimicrobial Susceptibility and Synergy Studies of Stenotrophomonas maltophilia Isolates from Patients with Cystic Fibrosis. Antimicrob. Agents Chemother. 48: 168-171 [Abstract] [Full Text]  
• Gibson, R. L., Burns, J. L., Ramsey, B. W. (2003). Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis. Am. J. Respir. Crit. Care Med. 168: 918-951 [Abstract] [Full Text]  
• Miller, M. B., Gilligan, P. H. (2003). Laboratory Aspects of Management of Chronic Pulmonary Infections in Patients with Cystic Fibrosis. J. Clin. Microbiol. 41: 4009-4015 [Full Text]  
• Saiman, L., Burns, J. L., Larone, D., Chen, Y., Garber, E., Whittier, S. (2003). Evaluation of MicroScan Autoscan for Identification of Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients. J. Clin. Microbiol. 41: 492-494 [Abstract] [Full Text]  
• Ferroni, A., Sermet-Gaudelus, I., Abachin, E., Quesne, G., Lenoir, G., Berche, P., Gaillard, J.-L. (2002). Use of 16S rRNA Gene Sequencing for Identification of Nonfermenting Gram-Negative Bacilli Recovered from Patients Attending a Single Cystic Fibrosis Center. J. Clin. Microbiol. 40: 3793-3797 [Abstract] [Full Text]  
• Saiman, L., Chen, Y., Gabriel, P. S., Knirsch, C. (2002). Synergistic Activities of Macrolide Antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans Isolated from Patients with Cystic Fibrosis. Antimicrob. Agents Chemother. 46: 1105-1107 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Saiman, L. Articles by Whittier, S. Search for Related Content PubMed PubMed Citation Articles by Saiman, L. Articles by Whittier, S.